3 Factor Indexing’s Charles River Laboratories CRL Stock Holding History

3 Factor Indexing’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$227	Hold	1	–	–	﹤0.01%	268
2026 Q1	$173	Buy	+1	New	+$185	﹤0.01%	315

Other funds holding CRL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

3 Factor Indexing's CRL Position: Q2 2026 in Review

3 Factor Indexing held its Charles River Laboratories (CRL) position steady in Q2 2026 at 1 share worth $227. The position accounts for ﹤0.01% of the portfolio, ranked #268.

3 Factor Indexing first reported a position in CRL in Q1 2026 and has held it in 2 quarters since. 531 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

3 Factor Indexing held 1 share of Charles River Laboratories worth $227 as of Q2 2026.
3 Factor Indexing left its Charles River Laboratories share count unchanged in Q2 2026.
Charles River Laboratories made up ﹤0.01% of 3 Factor Indexing's portfolio in Q2 2026, its #268 holding.
3 Factor Indexing first reported a position in Charles River Laboratories in Q1 2026 and has held it in 2 quarters since.
531 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on 3 Factor Indexing's 13F filing for Q2 2026, filed 8 Jul 2026.